Online inquiry

IVTScrip™ mRNA-Anti-SOST, AMG 785 (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2680MR)

This product GTTS-WQ2680MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets SOST gene. The antibody can be applied in Low bone mineral density research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_025237.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 50964
UniProt ID Q9BQB4
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SOST, AMG 785 (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ2680MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10756MR IVTScrip™ mRNA-Anti-ADAMTSL5&ALB, M-6495(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA M-6495
GTTS-WQ8312MR IVTScrip™ mRNA-Anti-GLP1R, HM-12525A(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA HM-12525A
GTTS-WQ1426MR IVTScrip™ mRNA-Anti-MUC16, ACA125(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ACA125
GTTS-WQ10051MR IVTScrip™ mRNA-Anti-FN1, L19-IL-2(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA L19-IL-2
GTTS-WQ8590MR IVTScrip™ mRNA-Anti-FOLH1, HuJ591-DOTA(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA HuJ591-DOTA
GTTS-WQ11227MR IVTScrip™ mRNA-Anti-pcrV&psl, MEDI3902(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MEDI3902
GTTS-WQ6876MR IVTScrip™ mRNA-Anti-CX3CL1, E-6011(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA E-6011
GTTS-WQ1633MR IVTScrip™ mRNA-Anti-F10&F9, ACE-910(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ACE-910
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW